MX2017012220A - Composiciones adyuvantes y metodos relacionados. - Google Patents

Composiciones adyuvantes y metodos relacionados.

Info

Publication number
MX2017012220A
MX2017012220A MX2017012220A MX2017012220A MX2017012220A MX 2017012220 A MX2017012220 A MX 2017012220A MX 2017012220 A MX2017012220 A MX 2017012220A MX 2017012220 A MX2017012220 A MX 2017012220A MX 2017012220 A MX2017012220 A MX 2017012220A
Authority
MX
Mexico
Prior art keywords
present disclosure
related methods
composition
adjuvant compositions
adjuvant composition
Prior art date
Application number
MX2017012220A
Other languages
English (en)
Inventor
J Miller Timothy
Ann Pfannenstiel Mary
Original Assignee
Vaxliant Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxliant Llc filed Critical Vaxliant Llc
Publication of MX2017012220A publication Critical patent/MX2017012220A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción proporciona una composición adyuvante que es adecuada para administración inyectable, así como transdérmica. La composición adyuvante, en general, comprende un lipófilo, un polímero de ácido acrílico o metacrílico, solución salina, colesterol, una saponina e hidróxido de sodio. También se proporciona una composición de vacuna que incluye, en general, la composición de vacuna de la presente descripción y un componente de ADN. También se proporciona un método de vacunación de animales y humanos que utiliza la composición adyuvante de la presente descripción.
MX2017012220A 2015-03-24 2016-03-24 Composiciones adyuvantes y metodos relacionados. MX2017012220A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562137659P 2015-03-24 2015-03-24
PCT/US2016/024003 WO2016154432A1 (en) 2015-03-24 2016-03-24 Adjuvant compositions and related methods

Publications (1)

Publication Number Publication Date
MX2017012220A true MX2017012220A (es) 2018-02-09

Family

ID=56973861

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012220A MX2017012220A (es) 2015-03-24 2016-03-24 Composiciones adyuvantes y metodos relacionados.

Country Status (8)

Country Link
US (2) US9636397B2 (es)
EP (1) EP3273950A4 (es)
JP (1) JP6925277B2 (es)
AU (1) AU2016235059B2 (es)
BR (1) BR112017020175A2 (es)
CA (1) CA2979556C (es)
MX (1) MX2017012220A (es)
WO (1) WO2016154432A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195261B2 (en) 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
CA2979556C (en) * 2015-03-24 2023-07-18 VaxLiant, LLC Adjuvant compositions and related methods
GB201616904D0 (en) * 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
AU2018275672A1 (en) 2017-05-31 2020-01-16 Texas Tech University System Methods and devices for the treatment of food allergies
CN111954541A (zh) 2018-01-25 2020-11-17 Acm生物实验室私人有限公司 包含可溶性包封抗原的聚合物囊泡以及其制备方法和用途
CA3106341A1 (en) * 2018-07-13 2020-01-16 Biomune Company New vaccines against avian reoviruses
EP3849600A1 (en) 2018-09-12 2021-07-21 ACM Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
CN114502191A (zh) 2019-08-01 2022-05-13 Acm生物实验室私人有限公司 通过施用具有关联的抗原的聚合物囊泡群和具有关联的佐剂的聚合物囊泡群来引发免疫应答的方法以及包含这两种聚合物囊泡群的组合物
WO2021214339A2 (en) 2020-04-24 2021-10-28 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
WO2022003155A1 (en) * 2020-07-03 2022-01-06 Statens Serum Institut A dna plasmid sars-coronavirus-2/covid-19 vaccine
CA3193643A1 (en) 2020-12-11 2022-06-16 Madhavan Nallani Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
AU2022216818A1 (en) 2021-02-02 2023-07-27 Acm Biolabs Pte Ltd Sole use of polymersome associated adjuvant for stimulating an immune response
JP2024518710A (ja) 2021-04-12 2024-05-02 エイシーエム バイオラブズ プライベート リミテッド 可溶性封入ポリヌクレオチドとイオン化可能脂質とを含むポリマーソームならびにその作製および使用方法
CN113913395B (zh) * 2021-10-19 2022-06-14 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 人工重组的h5n8流感病毒及其制备方法和应用
WO2023161378A1 (en) 2022-02-23 2023-08-31 Acm Biolabs Pte Ltd Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
HUE043493T2 (hu) * 2008-06-27 2019-08-28 Zoetis Services Llc Új adjuváns készítmények
US10092580B2 (en) * 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US20110207952A1 (en) * 2010-02-22 2011-08-25 Rafael Avila Cholesterol extraction from algae and preparation of vegan vitamin d3
EP4218808A3 (en) * 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions
AU2013337651B2 (en) 2012-11-01 2018-12-13 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US10195261B2 (en) 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
AU2015353376B2 (en) * 2014-11-26 2021-03-25 Huvepharma, Inc. Adjuvant compositions and related methods
CA2979556C (en) 2015-03-24 2023-07-18 VaxLiant, LLC Adjuvant compositions and related methods

Also Published As

Publication number Publication date
EP3273950A4 (en) 2019-04-24
WO2016154432A1 (en) 2016-09-29
AU2016235059B2 (en) 2021-04-01
AU2016235059A1 (en) 2017-10-05
US10265395B2 (en) 2019-04-23
JP2018510874A (ja) 2018-04-19
US20160279237A1 (en) 2016-09-29
US20170202959A1 (en) 2017-07-20
BR112017020175A2 (pt) 2018-06-12
CA2979556C (en) 2023-07-18
EP3273950A1 (en) 2018-01-31
JP6925277B2 (ja) 2021-08-25
US9636397B2 (en) 2017-05-02
CA2979556A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
MX2017012220A (es) Composiciones adyuvantes y metodos relacionados.
PH12018500855A1 (en) Herpes simplex virus vaccine
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
CL2018001053A1 (es) Vacuna contra el virus sincicial respiratorio
EP4349404A3 (en) Respiratory virus vaccines
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
EA201790398A1 (ru) Способы лечения заболевания печени
WO2017070616A3 (en) Sexually transmitted disease vaccines
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
TW201613556A (en) Swine virus vaccines that are liquid stable
BR112017025705A2 (pt) método de liberação de glicosídeos de esteviol de uma célula hospedeira, método de recuperação de glicosídeos de esteviol de uma composição e composição
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
BR112017005428A2 (pt) método para tratar uma formação subterrânea, sistema para realizar o método de tratamento de uma formação subterrânea, sistema, composição para o tratamento de uma formação subterrânea e método de preparar uma composição para o tratamento de uma formação subterrânea
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
EP3364985A4 (en) METHOD FOR GENERATING MANIPULATED DENDRITIC CELL LINES FROM HUMAN PRIMARY BLOOD
MX2017006744A (es) Composiciones adyuvantes y metodos relacionados.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
MX357431B (es) Vacuna contra garrapatas rhipicephalus.